NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 1 to 25 of 1411

Display Results as:

Centers of Biomedical Research Excellence (COBRE) (P20 Clinical Trial Optional) - PAR-18-266

Organization: NIGMS 

Posting Date: 11-30-2017 

Expiration Date: 01-25-2019 

Activity Code: P20 

Summary: The National Institute of General Medical Sciences (NIGMS) invites applications for Centers of Biomedical Research Excellence (COBRE) from investigators at biomedical research institutions that award doctoral degrees in the health sciences or sciences related to health or at independent biomedical research institutes with ongoing biomedical research programs funded by the NIH or other federal agencies within Institutional Development Award (IDeA) eligible states. The objectives of the COBRE initiative is to strengthen an institution's biomedical research infrastructure through the establishment of a thematic multi-disciplinary center and to enhance the ability of investigators to compete independently for complementary National Institutes of Health (NIH) individual research grants or other external peer-reviewed support. COBRE awards are supported through the IDeA Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in states with historically low aggregate success rates for grant awards from the NIH.  

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) - PAR-18-226

Organization: NIDA 

Posting Date: 11-30-2017 

Expiration Date: 10-20-2018 

Activity Code: DP1 

Summary: Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. 

Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54 Clinical Trial Optional) - PAR-18-265

Organization: NIGMS 

Posting Date: 11-30-2017 

Expiration Date: 10-03-2019 

Activity Code: U54 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support the development of infrastructure and other resources required for the conduct of Clinical and Translational Research (CTR) in IDeA-eligible states. IDeA-CTR Centers are expected to provide added value to the biomedical research efforts in the participating institutions through support of activities that cannot easily be provided through standard research grant awards. The proposed activities will provide the infrastructure and resources that will enhance the competitiveness of the investigators to obtain additional funding for clinical and translational research. Applicants must establish a statewide network of collaborating and partnering institutions/organizations. Other institutions/organizations outside the state may be included if forming a network of wider reach. Since only one award will be made per IDeA-eligible state, only one application should be submitted per state. 

Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE)(P20 Clinical Trial Optional) - PAR-18-264

Organization: NIGMS 

Posting Date: 11-30-2017 

Expiration Date: 09-29-2018 

Activity Code: P20 

Summary: The National Institute of General Medical Sciences (NIGMS) of the NIH invites applications for renewal of eligible Centers of Biomedical Research Excellence (COBRE) grants. The objective of the COBRE initiative is to strengthen an institution's biomedical research infrastructure through the establishment of a thematic, multi-disciplinary center and to enhance the ability of investigators to compete independently for National Institutes of Health (NIH) individual research grants or other external peer-reviewed support. COBRE awards are supported through the Institutional Development Award (IDeA) Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in IDeA states. 

NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) - PAR-18-225

Organization: NIDA 

Posting Date: 11-30-2017 

Expiration Date: 01-08-2020 

Activity Code: P30 

Summary: NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to drug abuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged. An application should integrate and promote research in existing funded projects, to achieve new and creative directions. It is expected that individual core activities reflect a relationship to the integrating theme of the Center and the Center is expected to provide research opportunities and experiences to new investigators, and share findings, data and their resources, consistent with achieving the goals of the program.  

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) - PAR-18-224

Organization: NIDA 

Posting Date: 11-30-2017 

Expiration Date: 01-08-2019 

Activity Code: P50 

Summary: This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDAs mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are required. The P50 Center of Excellence is expected to foster the career development and mentoring of new investigators who would be given meaningful roles to play in the Center projects. A goal of this program is to create NIDA Centers that are national community resources for furthering drug abuse research by sharing their findings, their data, and their resources as appropriate for researchers to use and build upon and to advance research in this field.  

NIMH Research Education Mentoring Programs for HIV/AIDS Researchers (R25) - PAR-17-485

Organization: NIMH 

Posting Date: 09-15-2017 

Expiration Date: 09-08-2020 

Activity Code: R25 

Summary: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Mental Health (NIMH) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs and advance the priorities outlined in the Office of AIDS Research (OAR) Annual Strategic Plan and the research program priorities of the NIMH Division of AIDS Research (DAR). 

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21 Clinical Trial Optional) - PAR-18-242

Organization: FIC 

Posting Date: 11-30-2017 

Expiration Date: 09-01-2018 

Activity Code: R21 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory/developmental research applications that propose to conduct research to develop or adapt innovative mobile health (mHealth) technology specifically suited for low and middle income countries (LMICs) and determine the health-related outcomes associated with implementation of the technology. Of highest interest are innovative, well-designed multidisciplinary projects that aim to generate generalizable knowledge for the field. 

Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional) - PAR-18-437

Organization: NIDA 

Posting Date: 01-09-2018 

Expiration Date: 12-19-2020 

Activity Code: R21 

Summary: The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio. The proposed research should: (1) test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking; and/or (2) develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research.  

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional) - RFA-DA-18-019

Organization: NIDA 

Posting Date: 12-06-2017 

Expiration Date: 08-15-2020 

Activity Code: DP1 

Summary: The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV. 

Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11-Clinical Trial Not Allowed) - PAR-18-335

Organization: NIAID 

Posting Date: 10-31-2017 

Expiration Date: 08-01-2020 

Activity Code: G11 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from research institutions in low- to middle-income countries (LMIC) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The ultimate goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in low to middle-income countries. 

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional) - RFA-DA-18-020

Organization: NIDA 

Posting Date: 12-06-2017 

Expiration Date: 09-08-2020 

Activity Code: UG3/UH3 

Summary: The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval. 

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional) - PAR-18-222

Organization: NIDA 

Posting Date: 11-30-2017 

Expiration Date: 11-14-2020 

Activity Code: R01 

Summary: As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.  

Multi-Site Pilot and Feasibility Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional) - PAR-18-223

Organization: NIDA 

Posting Date: 11-30-2017 

Expiration Date: 11-14-2020 

Activity Code: R34 

Summary: As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA and NIAAA join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.  

Strategies to Increase Delivery of Guideline-Based Care to Populations with Health Disparities (R01 Clinical Trial Optional) - PAR-18-133

Organization: NHLBI 

Posting Date: 11-30-2017 

Expiration Date: 06-22-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) invites applications to conduct innovative and feasible studies to test strategies to accelerate the adoption of guideline-based recommendations into clinical practice among populations with health disparities. Applications that propose strategies with a focus on providers who care for clinical populations with excess burden of cardiovascular, lung, blood, and sleep diseases and disorders, in concert with the health care delivery systems in which they practice, are strongly encouraged. Applications that test systems, infrastructures, and strategies to implement guideline-based care for NHLBI disorders in clinical care settings are also of high programmatic interest.  

Image-guided Drug Delivery (R01 Clinical Trial Optional) - PAR-18-252

Organization: NCI 

Posting Date: 11-30-2017 

Expiration Date: 11-23-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.  

NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trials Optional) - PAR-18-533

Organization: NIDCD 

Posting Date: 12-21-2017 

Expiration Date: 02-23-2021 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact. 

Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Optional) - PAR-18-112

Organization: NIDDK 

Posting Date: 11-02-2017 

Expiration Date: 09-08-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. 

Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) - PAR-18-292

Organization: NCI 

Posting Date: 11-30-2017 

Expiration Date: 06-16-2018 

Activity Code: K12 

Summary: This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs from applicant organizations that propose to promote the training and career development of clinical trials researchers. It is intended to increase the number of clinicians (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s or equivalent) and non-clinician postdoctoral researchers trained to design and test clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II, and Phase III clinical trials).  

Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R21 Clinical Trial Optional) - PA-18-492

Organization: NCI 

Posting Date: 12-11-2017 

Expiration Date: 05-08-2021 

Activity Code: R21 

Summary: This funding opportunity announcement (FOA) encourages research to understand how information technology (IT) can support systematic screening and treatment of depression in cancer patients in a variety of oncology practice settings. The goals of this FOA are to: identify new, IT-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations. 

End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional) - PA-18-499

Organization: NINR 

Posting Date: 12-15-2017 

Expiration Date: 05-08-2021 

Activity Code: R21 

Summary: This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. 

Underactive Bladder and Detrusor Activity in Aging (R03 Clinical Trial Optional) - PA-18-571

Organization: NIA 

Posting Date: 01-11-2018 

Expiration Date: 05-08-2021 

Activity Code: R03 

Summary: This Funding Opportunity Announcement (FOA) invites pilot/feasibility projects that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Pilot/feasibility research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. 

Underactive Bladder and Detrusor Activity in Aging (R21 Clinical Trial Optional) - PA-18-572

Organization: NIA 

Posting Date: 01-11-2018 

Expiration Date: 05-08-2021 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. 

Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R21 Clinical Trial Optional) - PAR-18-250

Organization: NCI 

Posting Date: 11-30-2017 

Expiration Date: 06-14-2019 

Activity Code: R21 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to provide support for innovative and promising intervention research designed to improve smoking cessation outcomes among socioeconomically disadvantaged populations. Specifically, this FOA is intended to stimulate research efforts aimed at the development of smoking cessation interventions that: 1) are targeted to socioeconomically disadvantaged populations, and 2) could be made scalable for broad population impact. Applicants may propose projects that develop and test novel cessation interventions with the potential to be scaled up, as well as projects that focus on enhancing the effectiveness, quality, accessibility, utilization, and cost-effectiveness of currently scaled smoking cessation interventions. This FOA provides funding for up to 2 years for protocol development and early phase, pilot, or exploratory projects. 

Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R01 Clinical Trial Optional) - PAR-18-251

Organization: NCI 

Posting Date: 11-30-2017 

Expiration Date: 06-14-2019 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to provide support for highly innovative and promising intervention research designed to improve smoking cessation outcomes among socioeconomically disadvantaged populations. Specifically, this FOA is intended to stimulate research efforts aimed at the development of smoking cessation interventions that: 1) are targeted to socioeconomically disadvantaged populations, and 2) could be made scalable for broad population impact. Applicants may propose projects that develop and test novel cessation interventions with the potential to be scaled up, as well as projects that focus on enhancing the effectiveness, quality, accessibility, utilization, and cost-effectiveness of currently scaled smoking cessation interventions. This FOA provides funding for up to 5 years for research planning, intervention delivery, and follow-up activities. 

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top